About the Company

Celladon (NasdaqGM: CLDN) is a clinical-stage biopharmaceutical company developing MYDICAR, a gene therapy for the treatment of advanced heart failure. The Company is conducting a 250 patient Phase IIb trial of MYDICAR; enrollment is complete and data are expected in April 2015. The FDA has granted Breakthrough Therapy Designation to the MYDICAR program. The Company is conducting several additional proof-of-concept trials to expand the potential label for MYDICAR therapy to include additional patient groups.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research